echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In 2020, China's drug market will have a rare negative growth, innovative drugs become the driving force of growth.

    In 2020, China's drug market will have a rare negative growth, innovative drugs become the driving force of growth.

    • Last Update: 2020-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On August 13th, the 2020 Xipu will open in Boao, Hainan, with the theme of "Day by Day - A New Era of Health Management throughout the Life Cycle".
    opening day, macro-environmental analysis, policy research interpretation, market panoramic insights, heavy data release, excellent speech reports, forum exchange collision ... A thought feast came, drug retail market, capital market, innovative drug market has attracted much attention, released the social pharmacy value highlights, large health industry investment blowout, the commercialization of innovative drugs and other signals.
    The value of social pharmacies highlights the latest data on the drug market released by Zhongkang CMH, showing that in 2019, the total size of the entire Chinese pharmaceutical market (excluding medicinal herbs, Chinese medicine tablets and formula particles) reached 1.82 trillion yuan, an increase of 8.9% over 2018, a rebound from the previous year.
    1: The size of the 400 million yuan across the country's drug market was affected by the outbreak, and in the first quarter of 2020, the drug terminal market declined sharply.
    expected China's drug market to be about 1.78 trillion yuan in full 2020, down 2.3 percent from 2019, with a rare negative growth.
    , in 2019, the grade hospital market accounted for 68.9% of the total drug market, and retail pharmacies accounted for 18.8% of the total drug market.
    Figure 2: In the 100-channel market share retail market, the overall size of retail terminals continued to increase, reaching 455.5 billion yuan in 2019, an increase of 4.7% in 2019, with a slight slowdown in growth.
    figure 3: National retail pharmacy terminal size and growth rate (MAT: rolling annual data) as an important part of the ecology of the large health industry, social pharmacies are natural health education places, in the life cycle of health management plays a very important role.
    of the epidemic, social pharmacies as the supply of medical supplies network the most, access to the strongest window, the role is more prominent.
    , LED by epidemic-related drugs, protective supplies and anti-killing products, the sales of MAT2020Q1 retail pharmacy terminals amounted to 461.6 billion yuan, up 4.9% YoY.
    with the dynamic adjustment of the medical insurance catalogue, the separation of medicines, the gradual landing of national procurement and other medical reform policies, the importance of the drug retail market will be further enhanced.
    health industry investment blowout big health industry is related to the national economy and people's livelihood of the basic and strategic industries, in line with the requirements of human development and the development of the times, favored by investors.
    statistics, the current global stock market value, the market value of large health industry-related stocks accounted for about 13% of the total market value.
    , especially in developed countries, the large health industry has become a powerful driving force for the growth of the entire national economy.
    "Healthy China 2030" program outline, china's total health service industry will reach more than 8 trillion yuan by 2020 and 16 trillion yuan by 2030.
    experienced the epidemic of this national health education, the demand for large health industry ushered in a major upgrade, large health industry has become a new growth pole, major cities compete to build large health industry clusters, 1000 large health industry investment boom.
    The current Sipu Capital Summit also reflects from the side of the large health industry investment boom, not only the scale of participation in the new high, but also the market value of listed companies participating in the meeting also reached a new high, accounting for about half of the total market value of the A-share pharmaceutical sector.
    health has been the focus of attention in China's capital markets, with 10.79 per cent of equity investment in 2019, the second-highest of any industry, according to health data.
    is not difficult to foresee, with the arrival of a new era of health management throughout the life cycle, as a potentially huge sunrise industry, large health industry investment is expected to usher in a blowout.
    the commercialization of innovative drugs in the great health industry ecology, innovative drugs can be said to be the pearl of the industry, is a huge potential incremental market, is becoming the industry's new growth engine.
    years, benefiting from the reform of China's drug review and approval system, the number of innovative drugs approved in China has increased significantly, the time of approval has been significantly shortened, and China's innovative drugs ushered in a period of rapid development.
    , the State Drug Administration issued the "2019 Drug Review Report" shows that in 2019, the Drug Review Center accepted a total of 700 applications for registration of one class of innovative drugs (319 varieties), the number of varieties increased by 20.8% compared to 2018.
    the approval and approval of the drug, in 2019, the Drug Review Center reviewed 10 varieties of the listed 1 class of innovative drugs, and reviewed 58 varieties (including new adaptations) of imported original drugs.
    driven by many positive policies, not only is the market of innovative drugs accelerating, but the commercialization of innovative drugs is also accelerating.
    ability to commercialize innovative drugs is becoming more and more critical in the future market competition, whether it is health care negotiations, channel selection, or academic promotion, are facing new changes brought about by the new rules of the game.
    health care negotiations have become a compulsory course for the commercialization of innovative drugs.
    years, more and more innovative drugs have been negotiated into the health-care list.
    In last year's medicare catalog adjustment, 70 new drugs were negotiated to be included in the National Health Care Drug Catalog, and the most successful drugs negotiated were new and of high clinical value in recent years, sending a clear signal of support for drug innovation.
    addition, the growing maturity of DTP pharmacies provides a new channel for the commercialization of innovative drugs.
    Compared with the entry of innovative drugs into the hospital market through a series of admission links, such as tender procurement, hospital procurement list, physician prescriptions, DTP pharmacy's time-available advantages are obvious, is attracting more and more innovative pharmaceutical companies to participate.
    at the same time, health commercial insurance, an important supplement to the payment side, is also on the rise.
    2019, the original insurance premium income for health insurance was 706.6 billion yuan, up 29.70 percent year-on-year, according to the China Banking Regulatory Commission.
    first half of this year, health insurance premium income reached 400.3 billion yuan, up 16.5% YoY, continuing to maintain high growth.
    , as an important supplement to medical insurance, can promote the coordinated development between medical insurance, the pharmaceutical industry and medical services, and contribute to the rapid commercialization of innovative drugs for the benefit of the vast number of patients.
    China Health Industry Ecological Conference, Xipu will provide industry prospects and market hot spot analysis every year.
    the current indications, the construction of the whole life cycle health management model is the best way for the health industry to upgrade and realize the optimization of the supply side.
    : The Xipu Society, known as the China Health Industry (International) Eco-Conference (CHEO), is organized by Zhongkang Information and is held regularly in Boao, Hainan, every year in August.
    2020 Sip will hold the "Pharmaceutical Industry Cooperation and Development Summit" and "Healthy" around the five values of "Cooperation, Innovation, Science and Technology, Research and Development, Capital" with the theme of "Day by Day - A New Era of Health Management in the Full Life Cycle" Industry Capital Summit, Innovation Drug Development Summit, Health Technology Developers Sharing Conference, New Marketing Forum, Full Life Cycle Health Assurance Roundtable Forum, six value summits, more than 50 parallel forums and high-end business events, as well as 5 large-scale industrial events will be held during the same period.
    This year, more than 50,000 representatives of various health industry entities will attend, including 6,000 official representatives, including government agencies, 300 domestic and foreign capital institutions, 1000 domestic and foreign mainstream brand industries (innovative drugs, generic drugs, traditional Chinese medicine, Chinese medicine tablets, health care products, medical devices), 1800 Mainstream commercial retail enterprises, 100-plus new technology companies, 50-plus innovative research and development companies, 300-plus experts (two academicians, scientists, clinical experts, industry research experts), 30-plus commercial insurance institutions, 200-plus private health care services, 50-plus mainstream media inside and outside the industry.
    As China's prestigious health industry conference, Sipu will take "cooperation, innovation, science and technology, research and development, capital" as the core label, bringing together the health industry including pharmaceutical, business, capital, research and development, science and technology, health care, health services, financial insurance and other mainstream institutions, to build a global health industry conference, for the development of the health industry to provide "decision-making" and "connectivity" support.
    Sip will integrate forward-looking ideas and information exchange, strategic cooperation and communication, high-end industry image display, cross-border integration and other functions in one, with "responsibility and responsibility" of the spirit of Sipu to advocate the mainstream values of China's health industry, leading industry innovation and change.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.